MedTrace Logo

Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder

NCT06693609 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-02-17

No results posted yet for this study

Summary

This Phase 2 study (protocol number EMP-01-201) will determine the safety and tolerability of a short-term treatment with an oral dosage form of EMP-01 in adult participants with social anxiety disorder (SAD) and will assess exploratory efficacy of repeated doses of EMP-01 versus placebo.

Conditions

Interventions

DRUG

EMP-01

EMP-01 capsules

DRUG

EMP-01 Placebo

EMP-01 placebo capsules

Sponsors & Collaborators

  • EmpathBio, Inc.

    collaborator UNKNOWN

  • atai Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2026-02-12
Completion
2026-02-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06693609 on ClinicalTrials.gov